by
Following the approval of Casgevy for the treatment of sickle cell disease, a crusade of clinical trials are centering the therapeutic potential of CRISPR technologies.
Clustered regularly interspaced short palindromic repeats (CRISPR), building on earlier-developed techniques such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), has emerged as the most frequently used method of genome editing, with many new studies and trials gaining traction.
